主页   >    COVID-19   >   Covid-19 抑制剂

Ponatinib

Bcr-Abl and Multikinase Inhibitor

A03-900

Bulk

概述:

Highly potent pan-Bcr-Abl and multikinase inhibitor, suppressing the activity of native Bcr-Abl (IC50=0.37 nM) as well as the mutants T315I (IC50=2 nM), Q252H (IC50=0.44 nM), Y253F (IC50=0.3 nM), M351T (IC50=0.3 nM) and H396P (IC50=0.34 nM) (1). Also inhibits PDGFRα, c-SRC and c-KIT (IC50=1.1, 5.4 and 12.5 nM respectively) (2) as well as FGFR-mediated signaling (IC50<40 nM) (3). Protects against influenza A virus-induced death by suppressing cytokine storm in mouse models (4).

Genbank编号:

N/A


参考文献:

1. T O’Hare et al. Cancer Cell 2009 16:401. 2. JM Gozgit et al. Mol. Cancer Ther. 2011 10:1028. 3. JM Gozgit et al. Mol. Cancer Ther. 2012 11:690. 4. S Chen et al. Front Immunol. 2019 10:1393.




该产品没有相关的出版物。